The shingles vaccine is recommended for healthy adults age 50 or older, and also for anyone age 19 years or older who has a ...

A second-generation melanoma vaccine being developed at UVA Cancer Center improves long-term survival for melanoma patients compared with the first-generation vaccine, new research shows.

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

A small company developing a new shingles vaccine announced Monday that the venture capitalist Moncef Slaoui, who previously ran the U.S. government’s Operation Warp Speed Covid vaccine effort ...

A canine melanoma vaccine has received a full license from the US Department of Agriculture, the first therapeutic cancer vaccine approved for human or animal use. The San Diego–based Vical sees ...